SHAREHOLDER WARNING: Pomerantz Law Firm Reminds Losing Shareholders

SHAREHOLDER WARNING: Pomerantz Law Firm Reminds Losing Shareholders


NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Dx” or the “Company”). CODX and some of his officers. The class action lawsuit, filed in the United States District Court for the Southern District of New York and filed number 22-cv-07988, is filed on behalf of a group of individuals and entities who purchased Co-Dx’s publicly traded securities during the May 12, 2019 May 11, 2022 through the market close on August 11, 2022 (4:00 p.m. ET), inclusive (the “Collection Period”), to recover damages caused by the Defendants’ violations of the federal securities laws and pending remedies under Sections 10 (b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder against the Company and certain of its senior officials.

If you are a shareholder who purchased Co-Dx securities during the class action period, you have until October 17, 2022 to request the court to appoint you as lead plaintiff in the class action. A copy of the complaint is available at To discuss this promotion, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Persons inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Co-Dx claims to develop, manufacture and sell reagents used in diagnostic tests that work through the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detecting infectious diseases, Liquid biopsy for cancer screening and agricultural applications.

On April 6, 2020, Co-Dx announced that it had received an emergency use authorization from the Food and Drug Administration for its Logix Smart™ COVID-19 Detection Test, allowing it to continue selling the test to…

Read full story here

More to explorer